

Raphaela T Goldbach-Mansky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1372651/publications.pdf>

Version: 2024-02-01

151
papers

19,715
citations

19657

61
h-index

11607

135
g-index

157
all docs

157
docs citations

157
times ranked

21050
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>DDX58</i> (RIG-I)-related disease is associated with tissue-specific interferon pathway activation. <i>Journal of Medical Genetics</i> , 2022, 59, 294-304.	3.2	16
2	Excess Serum Interleukin-18 Distinguishes Patients With Pathogenic Mutations in <i>PSTPIP1</i> . <i>Arthritis and Rheumatology</i> , 2022, 74, 353-357.	5.6	19
3	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 601-613.	0.9	31
4	NEMO-NDAS: A Panniculitis in the Young Representing an Autoinflammatory Disorder in Disguise. <i>American Journal of Dermatopathology</i> , 2022, 44, e64-e66.	0.6	3
5	Protein kinase R is an innate immune sensor of proteotoxic stress via accumulation of cytoplasmic IL-24. <i>Science Immunology</i> , 2022, 7, eabi6763.	11.9	22
6	Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19. <i>Nature Medicine</i> , 2022, 28, 1050-1062.	30.7	144
7	Post-SARS-CoV-2 Vaccine Monitoring of Disease Flares in Autoinflammatory Diseases. <i>Journal of Clinical Immunology</i> , 2022, 42, 732-735.	3.8	3
8	Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. <i>Arthritis and Rheumatology</i> , 2022, 74, 1271-1283.	5.6	24
9	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE, PRAAS, SAVI, and AGS. <i>Arthritis and Rheumatology</i> , 2022, 74, 735-751.	5.6	23
10	Genetically programmed alternative splicing of NEMO mediates an autoinflammatory disease phenotype. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	15
11	Pathogenic insights from genetic causes of autoinflammatory inflammasomopathies and interferonopathies. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 819-832.	2.9	19
12	Human induced pluripotent stem cells generated from Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome patients with a homozygous mutation in the <i>PSMB8</i> gene (NIHTVBi016-A, NIHTVBi017-A, NIHTVBi018-A). <i>Stem Cell Research</i> , 2022, 62, 102820.	0.7	1
13	The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 807-821.	0.9	38
14	Hematologic abnormalities in Aicardi Goutières Syndrome. <i>Molecular Genetics and Metabolism</i> , 2022, 136, 324-329.	1.1	8
15	Developing guidelines for ultrarare rheumatic disorders: a bumpy ride. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1203-1205.	0.9	4
16	Neutrophilic dermatosis: a new skin manifestation and novel pathogenic variant in a rare autoinflammatory disease. <i>Australasian Journal of Dermatology</i> , 2021, 62, e276-e279.	0.7	5
17	Novel Majeed Syndrome Causing <i>LPIN2</i> Mutations Link Bone Inflammation to Inflammatory M2 Macrophages and Accelerated Osteoclastogenesis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1021-1032.	5.6	11
18	An immune-based biomarker signature is associated with mortality in COVID-19 patients. <i>JCI Insight</i> , 2021, 6, .	5.0	269

#	ARTICLE	IF	CITATIONS
19	Systematic evaluation of nine monogenic autoinflammatory diseases reveals common and disease-specific correlations with allergy-associated features. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 788-795.	0.9	12
20	Spectrum of Systemic Auto-Inflammatory Diseases in India: A Multi-Centric Experience. <i>Frontiers in Immunology</i> , 2021, 12, 630691.	4.8	11
21	Epicutaneous <i>Staphylococcus aureus</i> induces IL-36 to enhance IgE production and ensuing allergic disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	39
22	Case Report: Novel SAVI-Causing Variants in STING1 Expand the Clinical Disease Spectrum and Suggest a Refined Model of STING Activation. <i>Frontiers in Immunology</i> , 2021, 12, 636225.	4.8	18
23	Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function. <i>Blood</i> , 2021, 137, 2450-2462.	1.4	47
24	Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE. <i>Cell</i> , 2021, 184, 4464-4479.e19.	28.9	90
25	Baricitinib experience on STING-associated vasculopathy with onset in infancy: A representative case from Turkey. <i>Clinical Immunology</i> , 2020, 212, 108273.	3.2	38
26	A clinical score to guide in decision making for monogenic type I IFNopathies. <i>Pediatric Research</i> , 2020, 87, 745-752.	2.3	16
27	A promiscuous inflammasome sparks replication of a common tumor virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1722-1730.	7.1	36
28	STEEP mediates STING ER exit and activation of signaling. <i>Nature Immunology</i> , 2020, 21, 868-879.	14.5	82
29	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	12.6	1,983
30	Human Autoinflammatory Diseases Mediated by NLRP3-, Pysin-, NLRP1-, and NLRC4-Inflammasome Dysregulation Updates on Diagnosis, Treatment, and the Respective Roles of IL-1 and IL-18. <i>Frontiers in Immunology</i> , 2020, 11, 1840.	4.8	67
31	A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI). <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1204-1208.e6.	2.9	45
32	IL-1 mediated autoinflammatory diseases. , 2020, , 643-684.		0
33	Autoinflammatory diseases affecting bone and joints, and autoinflammatory interferonopathies. , 2020, , 685-720.		1
34	Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. <i>Arthritis Research and Therapy</i> , 2020, 22, 69.	3.5	39
35	Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. <i>Journal of Clinical Investigation</i> , 2020, 130, 1669-1682.	8.2	142
36	Chronic Atypical Neutrophilic Dermatitis with Lipodystrophy and Elevated Temperature Syndrome (CANDLE)/Proteasome-Associated Autoinflammatory Syndromes (PRAAS). , 2020, , 156-161.		1

#	ARTICLE	IF	CITATIONS
37	Introduction to Autoinflammatory Diseases. , 2020, , 401-405.		0
38	Chronic Atypical Neutrophilic Dermatitis with Lipodystrophy and Elevated Temperature Syndrome (CANDLE)/Proteasome-Associated Autoinflammatory Syndromes (PRAAS). , 2020, , 1-6.		0
39	Neonatal-Onset Multisystem Inflammatory Disease (NOMID). , 2020, , 496-502.		0
40	Severe autoinflammation in 4 patients with C-terminal variants in cell division control protein 42 homolog (CDC42) successfully treated with IL-1 β inhibition. Journal of Allergy and Clinical Immunology, 2019, 144, 1122-1125.e6.	2.9	85
41	Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain, 2019, 142, e59-e59.	7.6	58
42	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.9	300
43	Novel proteasome assembly chaperone mutations in PSMG2/PAC2 cause the autoinflammatory interferonopathy CANDLE/PRAAS4. Journal of Allergy and Clinical Immunology, 2019, 143, 1939-1943.e8.	2.9	82
44	Classification of Genetically Defined Autoinflammatory Diseases. , 2019, , 167-201.		6
45	Cryopyrin-Associated Periodic Syndromes (CAPS). , 2019, , 347-365.		2
46	Systemic Autoimmunity in a Patient With CANDLE Syndrome. Journal of Investigational Allergology and Clinical Immunology, 2019, 29, 75-76.	1.3	13
47	Recurrent fevers, progressive lipodystrophy, and annular plaques in a child. Journal of the American Academy of Dermatology, 2019, 80, 291-295.	1.2	5
48	DDX58 and Classic Singleton-Merten Syndrome. Journal of Clinical Immunology, 2019, 39, 75-80.	3.8	37
49	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor-associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	2.0	16
50	Development of a Validated Interferon Score Using NanoString Technology. Journal of Interferon and Cytokine Research, 2018, 38, 171-185.	1.2	120
51	Rash, Fever, and Pulmonary Hypertension in a 6-Year-Old Female. Arthritis Care and Research, 2018, 70, 785-790.	3.4	7
52	Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood, 2018, 131, 1442-1455.	1.4	288
53	IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c χ iT-bet χ B cells in SLE. Nature Communications, 2018, 9, 1758.	12.8	392
54	Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients. Clinical Pharmacology and Therapeutics, 2018, 104, 364-373.	4.7	93

#	ARTICLE	IF	CITATIONS
55	JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. <i>Journal of Clinical Investigation</i> , 2018, 128, 3041-3052.	8.2	387
56	Updates on autoinflammatory diseases. <i>Current Opinion in Immunology</i> , 2018, 55, 97-105.	5.5	33
57	Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogramming. <i>Nature Communications</i> , 2018, 9, 3506.	12.8	192
58	Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7768-E7775.	7.1	150
59	In silico validation of the Autoinflammatory Disease Damage Index. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1599-1605.	0.9	27
60	Introduction: Autoinflammatory Syndromes Special Issue“hidden mysteries in the corners of autoinflammation. <i>International Immunology</i> , 2018, 30, 181-182.	4.0	1
61	Introduction to Autoinflammatory Diseases. , 2018, , 1-6.		0
62	Neonatal-Onset Multisystem Inflammatory Disease (NOMID). , 2018, , 1-6.		0
63	Mutations in Lyn Kinase Causes Changes in Neutrophil Function and Migration. <i>FASEB Journal</i> , 2018, 32, .	0.5	0
64	Familial chilblain lupus due to a gain-of-function mutation in STING. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 468-472.	0.9	247
65	Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood“Brain Barrier Function in Neonatal“Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal“Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation. <i>Arthritis and Rheumatology</i> , 2017, 69, 1325-1336.	5.6	50
66	Development of the autoinflammatory disease damage index (ADDI). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 821-830.	0.9	68
67	Deficiency of Interleukin-1 Receptor Antagonist (DIRA): Report of the First Indian Patient and a Novel Deletion Affecting IL1RN. <i>Journal of Clinical Immunology</i> , 2017, 37, 445-451.	3.8	43
68	Clinical, Endoscopic, and Histologic GI Manifestations of Behcet's Disease: Time to Redefine the Syndrome?. <i>Gastroenterology</i> , 2017, 152, S777.	1.3	0
69	Dermatologic Manifestations of Monogenic Autoinflammatory Diseases. <i>Dermatologic Clinics</i> , 2017, 35, 21-38.	1.7	38
70	Treatment of mucocutaneous manifestations in Beh“set“™s disease with anakinra: a pilot open-label study. <i>Arthritis Research and Therapy</i> , 2017, 19, 69.	3.5	56
71	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 942-947.	0.9	175
72	<i>NLRP3</i> mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7766-E7775.	7.1	117

#	ARTICLE	IF	CITATIONS
73	Brief Report: Clinical and Molecular Phenotypes of Low-Penetrance Variants of <i>NLRP3</i> : Diagnostic and Therapeutic Challenges. <i>Arthritis and Rheumatology</i> , 2017, 69, 2233-2240.	5.6	68
74	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 316-317.	2.9	1
75	Recurrent lipoatrophic panniculitis of children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 536-543.	2.4	20
76	Life-threatening NLR4-associated hyperinflammation successfully treated with IL-18 inhibition. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1698-1701.	2.9	282
77	Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist. <i>JCI Insight</i> , 2017, 2, .	5.0	35
78	TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies. <i>Journal of Clinical Investigation</i> , 2017, 127, 4488-4497.	8.2	126
79	Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1845-1854.	2.8	67
80	TCF11/Nrf1-Mediated Induction of Proteasome Expression Prevents Cytotoxicity by Rotenone. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 870-885.	5.4	33
81	Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus. <i>Journal of Molecular Medicine</i> , 2016, 94, 1111-1127.	3.9	101
82	Genetically defined autoinflammatory diseases. <i>Oral Diseases</i> , 2016, 22, 591-604.	3.0	22
83	Interstitial Lung Disease Caused by STING-associated Vasculopathy with Onset in Infancy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 639-642.	5.6	58
84	Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. <i>Rheumatology</i> , 2016, 55, 1499-1506.	1.9	110
85	Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 186-189.	1.2	64
86	ID: 6. <i>Cytokine</i> , 2015, 76, 58.	3.2	0
87	Identification of Interleukin-1 β -Producing Monocytes That Are Susceptible to Pyronecrotic Cell Death in Patients With Neonatal-Onset Multisystem Inflammatory Disease. <i>Arthritis and Rheumatology</i> , 2015, 67, 3286-3297.	5.6	14
88	Newly recognized Mendelian disorders with rheumatic manifestations. <i>Current Opinion in Rheumatology</i> , 2015, 27, 511-519.	4.3	23
89	Histologic and Immunohistochemical Features of the Skin Lesions in CANDLE Syndrome. <i>American Journal of Dermatopathology</i> , 2015, 37, 517-522.	0.6	39
90	Molecular Mechanisms in Genetically Defined Autoinflammatory Diseases: Disorders of Amplified Danger Signaling. <i>Annual Review of Immunology</i> , 2015, 33, 823-874.	21.8	230

#	ARTICLE	IF	CITATIONS
91	Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. <i>EBioMedicine</i> , 2015, 2, 351-355.	6.1	200
92	New monogenic autoinflammatory diseases—a clinical overview. <i>Seminars in Immunopathology</i> , 2015, 37, 387-394.	6.1	37
93	A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1714-1719.	0.9	59
94	Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. <i>Journal of Clinical Investigation</i> , 2015, 125, 4196-4211.	8.2	258
95	Monogenic autoinflammatory diseases. , 2015, , 1369-1391.		1
96	Brief Report: Anakinra Use During Pregnancy in Patients With Cryopyrin-Associated Periodic Syndromes. <i>Arthritis and Rheumatology</i> , 2014, 66, 3227-3232.	5.6	72
97	Classic Autoinflammatory Diseases. , 2014, , 517-550.		1
98	Autoinflammatory Diseases Predominantly Affecting Bone and Joints. , 2014, , 551-572.		0
99	Comprehensive Immunophenotyping of Cerebrospinal Fluid Cells in Patients with Neuroimmunological Diseases. <i>Journal of Immunology</i> , 2014, 192, 2551-2563.	0.8	130
100	An activating NLR4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. <i>Nature Genetics</i> , 2014, 46, 1140-1146.	21.4	585
101	Activated STING in a Vascular and Pulmonary Syndrome. <i>New England Journal of Medicine</i> , 2014, 371, 507-518.	27.0	1,074
102	Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. <i>New England Journal of Medicine</i> , 2014, 370, 911-920.	27.0	687
103	IL-1 Blockade in Autoinflammatory Syndromes. <i>Annual Review of Medicine</i> , 2014, 65, 223-244.	12.2	273
104	CARD14 Expression in Dermal Endothelial Cells in Psoriasis. <i>PLoS ONE</i> , 2014, 9, e111255.	2.5	52
105	A case of proteasome-associated auto-inflammatory syndrome with compound heterozygous mutations. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, e29-e32.	1.2	21
106	Monogenic Autoinflammatory Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, 701-734.	1.9	38
107	Monogenic autoinflammatory diseases: Concept and clinical manifestations. <i>Clinical Immunology</i> , 2013, 147, 155-174.	3.2	174
108	Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1064-1070.	0.9	27

#	ARTICLE	IF	CITATIONS
109	Deficiency of Interleukin-1 Receptor Antagonist Responsive to Anakinra. <i>Pediatric Dermatology</i> , 2013, 30, 758-760.	0.9	62
110	Detection of Base Substitution-Type Somatic Mosaicism of the NLRP3 Gene with >99.9% Statistical Confidence by Massively Parallel Sequencing. <i>DNA Research</i> , 2012, 19, 143-152.	3.4	51
111	DIRA, DITRA, and New Insights Into Pathways of Skin Inflammation. <i>Archives of Dermatology</i> , 2012, 148, 381.	1.4	60
112	The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca ²⁺ and cAMP. <i>Nature</i> , 2012, 492, 123-127.	27.8	795
113	A novel mutation in the interleukin-1 receptor antagonist associated with intrauterine disease onset. <i>Clinical Immunology</i> , 2012, 145, 77-81.	3.2	54
114	Interleukin 1 Receptor Antagonist Deficiency Presenting as Infantile Pustulosis Mimicking Infantile Pustular Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 747-52.	1.4	60
115	Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes. <i>Arthritis and Rheumatism</i> , 2012, 64, 2375-2386.	6.7	182
116	PSORS2 Is Due to Mutations in CARD14. <i>American Journal of Human Genetics</i> , 2012, 90, 784-795.	6.2	365
117	Rare and Common Variants in CARD14, Encoding an Epidermal Regulator of NF-kappaB, in Psoriasis. <i>American Journal of Human Genetics</i> , 2012, 90, 796-808.	6.2	306
118	Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. <i>Clinical and Experimental Immunology</i> , 2012, 167, 391-404.	2.6	123
119	Mutations in proteasome subunit β^2 type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. <i>Arthritis and Rheumatism</i> , 2012, 64, 895-907.	6.7	340
120	Homeostatic Tissue Responses in Skin Biopsies from NOMID Patients with Constitutive Overproduction of IL-1 β . <i>PLoS ONE</i> , 2012, 7, e49408.	2.5	36
121	Current Status of Understanding the Pathogenesis and Management of Patients With NOMID/CINCA. <i>Current Rheumatology Reports</i> , 2011, 13, 123-131.	4.7	113
122	High incidence of <i>NLRP3</i> somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: Results of an international multicenter collaborative study. <i>Arthritis and Rheumatism</i> , 2011, 63, 3625-3632.	6.7	247
123	A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: Description of two unrelated cases from Brazil. <i>Arthritis and Rheumatism</i> , 2011, 63, 4007-4017.	6.7	96
124	A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 309-314.	0.9	70
125	Cryopyrin-Associated Periodic Syndromes. <i>Otolaryngology - Head and Neck Surgery</i> , 2011, 145, 295-302.	1.9	74
126	MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2075-2081.	0.9	57

#	ARTICLE	IF	CITATIONS
127	Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7148-7153.	7.1	241
128	Protein kinase A regulates caspase-1 via Ets-1 in bone stromal cell-derived lesions: a link between cyclic AMP and pro-inflammatory pathways in osteoblast progenitors. Human Molecular Genetics, 2011, 20, 165-175.	2.9	31
129	The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates. Journal of Neuroimmunology, 2010, 223, 138-140.	2.3	44
130	Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: Finding the right balance in response to danger signals. Clinical Immunology, 2010, 135, 210-222.	3.2	39
131	Autoinflammatory Disease Reloaded: A Clinical Perspective. Cell, 2010, 140, 784-790.	28.9	429
132	Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis. Current Opinion in Rheumatology, 2010, 22, 1.	4.3	55
133	Blocking Interleukin-1 in Rheumatic Diseases. Annals of the New York Academy of Sciences, 2009, 1182, 111-123.	3.8	89
134	Autoinflammation: The prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. Journal of Allergy and Clinical Immunology, 2009, 124, 1141-1149.	2.9	129
135	An Autoinflammatory Disease with Deficiency of the Interleukin-1 Receptor Antagonist. New England Journal of Medicine, 2009, 360, 2426-2437.	27.0	892
136	Comparison of <i>Tripterygium wilfordii</i> Hook F Versus Sulfasalazine in the Treatment of Rheumatoid Arthritis. Annals of Internal Medicine, 2009, 151, 229.	3.9	196
137	Monogenic Autoinflammatory Syndromes. , 2009, , 33-49.		0
138	The spectrum of monogenic autoinflammatory syndromes: Understanding disease mechanisms and use of targeted therapies. Current Allergy and Asthma Reports, 2008, 8, 288-298.	5.3	62
139	A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor riloncept (interleukin-1 trap) in patients with familial cold autoinflammatory syndrome. Arthritis and Rheumatism, 2008, 58, 2432-2442.	6.7	210
140	S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis and Rheumatism, 2008, 58, 3924-3931.	6.7	186
141	The spectrum of autoinflammatory diseases: recent bench to bedside observations. Current Opinion in Rheumatology, 2008, 20, 66-75.	4.3	40
142	The Anesthetic Management of Children with Neonatal-Onset Multi-System Inflammatory Disease. Anesthesia and Analgesia, 2007, 105, 351-357.	2.2	14
143	The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis and Rheumatism, 2007, 56, 1273-1285.	6.7	362
144	Treatment of patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome: Comment on the article by Matsubara et al. Arthritis and Rheumatism, 2007, 56, 2099-2101.	6.7	4

#	ARTICLE	IF	CITATIONS
145	Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). <i>Pediatric Radiology</i> , 2007, 37, 145-152.	2.0	116
146	Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1 β Inhibition. <i>New England Journal of Medicine</i> , 2006, 355, 581-592.	27.0	853
147	Mutational analysis in neonatal-onset multisystem inflammatory disease: Comment on the articles by Frenkel et al and Saito et al. <i>Arthritis and Rheumatism</i> , 2006, 54, 2703-2704.	6.7	22
148	Magnetic resonance imaging in the evaluation of bone damage in rheumatoid arthritis: A more precise image or just a more expensive one?. <i>Arthritis and Rheumatism</i> , 2003, 48, 585-589.	6.7	50
149	New Concepts in the Treatment of Rheumatoid Arthritis. <i>Annual Review of Medicine</i> , 2003, 54, 197-216.	12.2	64
150	De novo <i>CIAS1</i> mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. <i>Arthritis and Rheumatism</i> , 2002, 46, 3340-3348.	6.7	727
151	The Tumor-Necrosis-Factor Receptor-associated Periodic Syndrome: New Mutations in TNFRSF1A, Ancestral Origins, Genotype-Phenotype Studies, and Evidence for Further Genetic Heterogeneity of Periodic Fevers. <i>American Journal of Human Genetics</i> , 2001, 69, 301-314.	6.2	328